ClinicalTrials.gg
CompletedNCT01477619Updated Feb 17, 2014

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

A Phase 1 interventional study of Tasimelteon in Healthy Volunteers, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-17.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon in the blood in smokers versus non-smokers. Additionally, this study will provide an assessment of the effect, if any, of age and body size on the safety and tolerability profile and the pharmacokinetics of tasimelteon.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Groups 1 and 2:

  1. Men or women between 18 - 55 years, inclusive;
  2. Smokers who test positive for cotinine at screening and baseline and smoke at least 10 cigarettes per day, for at least 6 months prior to screening (Group 1) OR Non-smokers [abstinence from smoking for at least 6 months before the screening visit and test negative for cotinine at screening and baseline (Group 2)] who are matched to Group 1 by gender, age (±10 years), and category [underweight/normal (≤ 24.99), overweight (25.00-29.99), and obese (≥ 30.00)];
  3. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is , without menses for 6 months before screening), or females of using an acceptable method of for a period of 35 days before the first dosing and females must have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam.
  4. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

    • Body temperature between 35.0-37.5 °C;
    • Systolic blood pressure between 90-150 mmHg;
    • Diastolic blood pressure between 50-95 mmHg;
    • Pulse rate between 50-100 bpm.

Group 3:

  1. Men or women 65 years of age or older;
  2. Non-smokers (abstinence from smoking for at least 6 months before the start of the study and test negative for cotinine at screening and baseline);
  3. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

    • Systolic blood pressure between 90-160 mmHg;
    • Diastolic blood pressure between 50-99 mmHg;
    • Pulse rate between 50-100 bpm.

Groups 1-3:

  1. Ability and acceptance to provide written ;
  2. Willing and able to comply with study requirements and restrictions;
  3. Subjects must be in good health as determined by past medical history, physical examination, , clinical laboratory tests and urinalysis;

Exclusion criteria

Exclusion Criteria:

  1. History of recent (within six months) drug or alcohol abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated by the laboratory assays conducted during the Screening Visit or at Baseline;
  2. Any major surgery within three months of Baseline or any minor surgery within one month;
  3. History or current evidence of cardiovascular, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction judged by the Investigator to be ;
  4. Any condition requiring the regular use of medication except those listed in Section 8.2;
  5. Use of any melatonin preparation chronically within 2 months prior to Day 1 or any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) within 60 days prior to Day 1.
  6. Exposure to any drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of baseline;
  7. Donation or loss of 400 mL or more of blood within two months prior to the Baseline Visit;
  8. Significant illness within the two weeks prior to Baseline;
  9. A known to tasimelteon or drugs similar to tasimelteon including melatonin;
  10. Pregnant or lactating females;
  11. History of liver disease and/or positive for one or more of the following serological results:

    • A positive antibody test (anti-HCV)
    • A positive surface antigen (HBsAg)
  12. A positive test result
  13. Any surgical or medical condition which might significantly alter the absorption, distribution or excretion of any drug. The Investigator should be guided by evidence of any of the following:

    • Clinically significant gastritis, ulcers, gastrointestinal or rectal bleeding within 5 years of the screening visit;
    • History of inflammatory bowel syndrome, major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
    • Pancreatic injury or pancreatitis within 5 years of the screening visit;
    • Clinically significant urinary obstruction or difficulty voiding within 3 years of the screening visit;
  14. Exposure (within 2 weeks of the Baseline Visit) of any over-the-counter medications including dietary supplements and/or herbal remedies, except those listed in Section 8.2;
  15. Use of any food or beverage containing grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats for at least 2 weeks before the Baseline Visit until the end of the study;
  16. Inability to be venipunctured and/or tolerate venous access;
  17. Subjects who are unable to read or speak English;
  18. Participation in a previous BMS-214778/VEC-162 trial;
  19. Any other sound medical reason as determined by the clinical Investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Smokers

    Split into BMI categories

    Drug: Tasimelteon

  • Experimental
    Non-Smokers

    Gender, age, and BMI matched to Smokers

    Drug: Tasimelteon

  • Experimental
    Elderly

    Drug: Tasimelteon

Interventions

  • 20mg single dose on Day 1

    Also known as: VEC-162, BMS-214778

06

What researchers measure

Primary outcomes

  1. Tasimelteon plasma concentrations and pharmacokinetics in smokers versus non-smokers

    Plasma concentrations and pharmacokinetics of tasimelteon of group 1 (smokers) will be compared to group 2 (non-smokers)

    Time frame: Day 1 - Day 2

  2. To assess the effect of weight, body mass index (BMI), and age on the pharmacokinetic profile of tasimelteon

    Pharmacokinetics of tasimelteon will be compared using all three groups (smokers, non-smokers and elderly). Group 1 and Group 2 will be gender, age and BMI category matched.

    Time frame: Day 1 -Day 2

Secondary outcomes

  1. To assess plasma concentrations and pharmacokinetics of tasimelteon metabolites (M3, M9, M11, M12, M13, and M14) in subjects who smoke compared to subjects who do not smoke.

    Composite of 24 hour pharmacokinetic parameters will be compared between group 1 (smokers) and group 2 (non-smokers)

    Time frame: Day 1 - Day 2

  2. To assess the effect of weight, BMI, and age on the pharmacokinetic profile of tasimelteon metabolites (M3, M9, M11, M12, M13, and M14).

    Composite of 24 hour pharmacokinetic parameters will be compared using all three groups (smokers, non-smokers and elderly). Group 1 and Group 2 will be gender, age and BMI category matched.

    Time frame: Day 1 - Day 2

  3. Tasimelteon safety and tolerability

    Safety of single dose as measured by adverse event reporting.

    Time frame: Day 1

07

Study locations

1 site
  • Bio-Kinetic Clinical Applications
    Springfield, Missouri, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2011
First posted
Nov 22, 2011
Start
Nov 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Feb 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01477619
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Nov 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Feb 17, 2014

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion